Profile Image

Dr Matt Dun

Cancer Institute NSW EC Fellow

School of Biomedical Sciences and Pharmacy

Career Summary

Biography

I am a highly motivated and dedicated medical researcher focused on identifying novel targets and improved therapies for the treatment of the most common and devastating types of cancer; acute myeloid leukaemia (AML), breast cancer and prostate cancer. I completed my PhD by publication, with distinction and in less than three years, receiving eleven national and international research awards along the way. My PhD was mentored by two of the Universities most respected researchers in Prof. John Aitken and A/Prof. Brett Nixon. The significant contributions made to my field of research by PhD resulted in my dissertation being awarded the Vice Chancellors Annual Award for Research High Degree Excellence in 2012, and subsequently has laid the foundations to achieve my ambitions of developing a successful and internationally competitive research program here at the University of Newcastle and the Hunter Medical Research Institute (HMRI).

My current research program in direct collaboration with Dr Nicole Verrills is focused on the characterisation of new anti-leukaemia drugs synthesised by our collaborators at the UNSW Chemistry Department (Prof Morris). This targeted anti-cancer approach is complemented by a program of discovery research focused on identifying the disease causing mutations caused by the acquisition of somatic and epigenetic mutations often seen in acute myeloid leukaemia patients. This work was recently recognised by the Cancer Institute of NSW awarded me an esteemed Early Career Research Fellowship 2014-2016 ('Identifying novel therapeutic targets for the treatment of acute myeloid leukaemia (AML)'). Further, thanks to the fantastic public advocacy achieved by the HMRI, I have been fortunate to receive funding from the Hunter Community. Specifically, generous support from Mrs Alyson Gearing enabled me to initiate a ground breaking investigation into the yet unknown disease causing mutations seen in AML. These investigations were conducted in collaboration with the University of Southern Denmark (Prof Larsen) in Odense Denmark in 2013. More recently, the Estate of the Late Mr James Scott Lawrie Project Grants has provided me with the necessary funding to continue my work into the development of a new treatment for AML in 2014, and in 2015 work has commencing focused on developing new treatment options for children diagnosed with AML.

I am very fortunate to have extensive national and international collaborators with field leading scientists and haematologists. These opportunities provide my group with access to the world's most sophisticated technologies. Using these technologies we are bridging the very large gap that currently exists between cancer genomics and proteomics. These sophisticated studies are helping us to identify new bona fide biomarkers for the development of new targeted therapies to treat AML, breast cancers and prostate cancer.

Aside from research, I am committed to scientific advocacy and the promoting of the achievements of young local researchers. For the past three years I have been a committee member of the Australian Society for Medical Research (ASMR). Locally I have formed the ASMR Newcastle committee which now hosts 'The ASMR Satellite Scientific Meeting' held annually at the HMRI. This meeting showcases the recent research achievements of young Hunter bases scientists and clinicians. The meeting also helps to encourage postgraduate and student interactions and fosters collaborations between researchers affiliated within the Faculty of Health and Medicine, the Faculty of Science and Information Technology and the HMRI.

It is my goal to continue to attract talented students to join my research program and to continue to generate the required support necessary for us to make these important medical discoveries to develop new treatments options for cancer patients.

If you are interesting in joining my team or supporting my research please contact me at: Matt.Dun@newcastle.edu.au.

Research Expertise
Since the complete of my PhD I commenced my postdoctoral training within the Faculty of Health and Medicine Cancer Priority Research Centre at the Hunter Medical Research Institute (HMRI), associated with the Hunter Cancer Research Alliance (HCRA) and in collaboration with the Calvary Mater Hospital Medical Oncology Department. My Research Program is focused on elucidating the biochemical mechanisms that underpin novel anti-cancer therapies for improved treatment regimens for acute myeloid leukaemia (AML) and breast cancer. In this context, my technical strengths in many aspects of cell analysis, including: characterisation of protein expression, proteomic profiling including iTRAQ and SILAC, phosphoproteomics, DNA mutational analysis, cellular imagery, identification of protein-protein interactions via immunoprecipitation, Far-Western blotting and Blue Native PAGE, cell culture, functional assays and the generation of recombinant proteins and polyclonal antibodies has been recognised. My ever growing knowledge and skill base has benefited from close association with national and international colleagues. Funding from the HMRI in 2013 enabled me to spend a month working at Institut for Biokemi og Molekylær Biologi at the Syddansk Universitet where I worked with experts in proteomic assays, including phosphoproteomics, membrane proteomics, glycoproteomics, iTRAQ and SILIC. These phosphoproteomics studies utilised Hunter AML patients samples and is allowing us to determine the effect of oncogenic signalling to help determine novel treatment targets and identify the disease causing mutations associated with recurrent DNA mutations seen in AML. These complex investigations are aimed at unravelling the pathogenesis of disease, with the resulting data providing us with a better understanding of each condition. Following this sabbatical I was fortunate to present my work on AML at the American Association of Cancer Research in Washington DC.

In 2013 I received the Australian Society for Medical Research Recipient of the NSW Office for Health and Medical Research Postdoctoral Award for Excellence in Medical Research. This award was presented at the ASMR NSW Scientific Meeting. Commencing 2014 my research program is strongly supported thanks to the Cancer Institute of NSW Early Career Research Fellowship. This funding is for three years and aims to 'Identify novel therapeutic targets for the treatment of Acute Myeloid Leukaemia'. These experiences are helping me to establishing a firm foundation for a productive career in cancer cell biology. My ambitions are to attract talented students and integrate my many technical skills on Australian patients samples and to use model systems to further elucidate the mechanisms of disease. Please contact me if you are interesting in joining my team. Matt.Dun@newcastle.edu.au

Teaching Expertise
• 2013: Lecturer, HUBS1202 Human Genomics and Biomolecular Analysis. • 2013: Head Demonstrator, HUBS3302 Bioinformatics and Functional Genomics. • 2012. Lecturer, HUBS1202 Human Genomics and Biomolecular Analysis. • 2012: Head Demonstrator, HUBS3302 Bioinformatics and Functional Genomics. • 2011: Lecturer and Head Demonstrator, BIOL2020 Animal Physiology & Development. • 2011: Head Demonstrator, BIOL3020 Reproductive Physiology & Development head demonstrator. • 2011: Demonstrator, BIOL3001 Advanced Laboratory Skills. • 2010: Lecturer and Head Demonstrator, BIOL2020 Animal Physiology & Development. • 2010: Head Demonstrator, BIOL3020 Reproductive Physiology & Development head demonstrator. • 2010: Demonstrator, BIOL3001 Advanced Laboratory Skills. • 2009: Head Demonstrator, BIOL2020 Animal Physiology & Development. • 2009: Head Demonstrator, BIOL3020 Reproductive Physiology & Development head demonstrator. • 2009: Demonstrator, BIOL3001 Advanced Laboratory Skills. I am a lecturer for the Bachelor of Biomedical Science degree specifically, HUBS1202 Human Genomics and Biomolecular Analysis and HUBS3302 Bioinformatics and Functional Genomics. During my PhD I carried a significant teaching load, lecturing 2nd year Physiology for Biotech/Science students and spending almost 500 hours as Laboratory Head Demonstrator. Also during my studies I played Rugby Union for the University of Newcastle and was awarded runner up for Sports Person of the Year, awarded a University Blue and represented NSW in rugby union for five consecutive years. I was also awarded the Representative Player of the Year for the Newcastle and Hunter Rugby Union and in the same year was awarded the NSW Country Rugby Union Championships Player of the Tournament.

Administrative Expertise
Professional memberships: • 2014 –, Hunter Cancer Research Alliance Flagship Program in Implementation Scientific Committee Member • 2014 –, Convenor of the Australian Society for Medical Research (ASMR) Satellite Scientific Meeting • 2013 –, Committee Member of the Australian Society for Medical Research (ASMR) • 2012 –, Member of the American Association of Cancer Research (AACR) • 2012 –, Member of the Australian Leukaemia and Lymphoma Group (ALLG) • 2012 –, Member of the Australian Society of Medical Research (ASMR) • 2011 – 2012. Society of Reproductive Biology (SRB) Australian Student Representative to council • 2010 – 2012. Young Investigators of Reproductive Biology Epididymis Council Co-Chair (International Society) • 2010 – 2012. Priority Research Centre Reproductive Biology Meetings Co-Organiser (Reproductive Sciences, Eggs to Embryos and Mothers and Babies Groups) • 2010. University of Newcastle Research Higher Degree Committee, Conference Organising Chair

Collaborations
• Dr Nicole Verrills Medical Biochemistry, The University of Newcastle and HMRI. • Prof Steve Ackland, Dr Jenntte Sakoff and Dr Jayne Gilbert, Medical Oncology, The Calvary Mater Hospital and HMRI. • Dr Anoop Enjeti, Clinical Haematologist, The Calvary Mater Hospital. • Prof Hubert Hondermarck, Professor of Medical Biochemistry, The University of Newcastle. • Prof Martin Larsen, Institute of Biochemistry and Molecular Biology, The University of Southern Denmark. • Prof Jonathan Morris and Hamish Toop, Chemistry Department, University of New South Wales. • Prof Adam McCluskey, Chemistry Department, The University of Newcastle and Australian Cancer Research Foundation Centre for Kinomics. • Nathan Smith, Analytical and Biomolecular Research Facility, Advanced Mass Spectrometry Unit, The University of Newcastle. • Prof Richard Locke, Dr Anthony Don and Dr Anchit Khanna Lowy Cancer Research Centre, Prince of Wales Clinical School, Faculty of Medicine, The University of New South Wales.


Qualifications

  • PhD (Biological Science), University of Newcastle
  • Bachelor of Biotechnology, University of Newcastle
  • Bachelor of Biotechnology (Honours), University of Newcastle

Keywords

  • Anti-Cancer Drug Targeting
  • Biochemical Assays
  • Biochemistry
  • Cancer
  • Chemical Proteomics
  • Leukaemia
  • Nucleic Acids
  • Phosphoproteomics
  • Protein Chemistry
  • Proteomics

Fields of Research

CodeDescriptionPercentage
060109Proteomics and Intermolecular Interactions (excl. Medical Proteomics)30
110106Medical Biochemistry: Proteins and Peptides (incl. Medical Proteomics)30
111201Cancer Cell Biology40

Professional Experience

UON Appointment

DatesTitleOrganisation / Department
1/01/2015 - 31/12/2016Cancer Institute NSW EC FellowUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/07/2013 - 29/11/2013Casual LecturerUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
25/07/2011 - 9/12/2011Casual AcademicUniversity of Newcastle
School of Environmental and Life Sciences
Australia
2/03/2009 - 24/07/2009Casual AcademicUniversity of Newcastle
School of Environmental and Life Sciences
Australia

Academic appointment

DatesTitleOrganisation / Department
1/12/2013 - Cancer Instititue NSW Early Career FellowshipCancer Instititue NSW
School of Biomedical Sciences and Pharmacy, Medical Biochemistry
Australia
1/01/2013 - Conference Chair - The Australian Society for Medical Research, Satellite Scientific Meeting ConvenorThe Australian Society for Medical Research
1/10/2011 - 1/12/2013HMRI Cancer Research Program Chemical Proteomics Postdoctoral FellowUniversity of Newcastle
HMRI Cancer Research Program
Australia

Membership

DatesTitleOrganisation / Department
1/01/2013 - Membership - The Australian Society for Medical ResearchThe Australian Society for Medical Research
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (1 outputs)

YearCitationAltmetricsLink
2010Dun MD, Mitchell LA, Aitken RJ, Nixon B, 'Sperm-zona pellucida interaction: Molecular mechanisms and the potential for contraceptive intervention', Fertility Control, Springer, Berlin 139-178 (2010) [B1]
CitationsScopus - 4
Co-authorsBrett Nixon, John Aitken

Journal article (13 outputs)

YearCitationAltmetricsLink
2015Faulkner S, Dun MD, Hondermarck H, 'Proteogenomics: emergence and promise.', Cell Mol Life Sci, 72 953-957 (2015)
DOI10.1007/s00018-015-1837-yAuthor URL
Co-authorsHubert Hondermarck
2015Faulkner S, Dun MD, Hondermarck H, 'Proteogenomics: Emergence and promise', Cellular and Molecular Life Sciences, 72 953-957 (2015)

Proteogenomics, or the integration of proteomics with genomics and transcriptomics, is emerging as the next step towards a unified understanding of cellular functions. Looking glo... [more]

Proteogenomics, or the integration of proteomics with genomics and transcriptomics, is emerging as the next step towards a unified understanding of cellular functions. Looking globally and simultaneously at gene structure, RNA expression, protein synthesis and posttranslational modifications have become technically feasible and offer a new perspective to molecular processes. Recent publications have highlighted the value of proteogenomics in oncology for defining the molecular signature of human tumors, and translation to other areas of biomedicine and life sciences is anticipated. This minireview will discuss recent developments, challenges and perspectives in proteogenomics.

DOI10.1007/s00018-015-1837-y
Co-authorsHubert Hondermarck
2015Nixon B, Bromfield EG, Dun MD, Redgrove KA, McLaughlin EA, Aitken RJ, 'The role of the molecular chaperone heat shock protein A2 (HSPA2) in regulating human sperm-egg recognition.', Asian J Androl, 17 568-573 (2015)
DOI10.4103/1008-682X.151395Author URL
Co-authorsBrett Nixon, Eileen Mclaughlin, John Aitken
2015Dun MD, Chalkley RJ, Faulkner S, Keene S, Avery-Kiejda K, Scott RJ, et al., 'Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis.', Mol Cell Proteomics, (2015)
DOI10.1074/mcp.M114.046110Author URL
Co-authorsHubert Hondermarck, Murray Cairns, Kelly Kiejda
2014Goldie BJ, Dun MD, Lin M, Smith ND, Verrills NM, Dayas CV, Cairns MJ, 'Activity-associated miRNA are packaged in Map1b-enriched exosomes released from depolarized neurons.', Nucleic Acids Research, 42 9195-9208 (2014) [C1]
DOI10.1093/nar/gku594Author URL
CitationsScopus - 4Web of Science - 3
Co-authorsChristopher Dayas, Nikki Verrills, Minjie Lin, Murray Cairns
2014Sadeqzadeh E, De Bock CE, Wojtalewicz N, Holt JE, Smith ND, Dun MD, et al., 'Furin processing dictates ectodomain shedding of human FAT1 cadherin', Experimental Cell Research, 323 41-55 (2014)
DOI10.1016/j.yexcr.2014.02.012
Co-authorsJanet Holt, Rick Thorne
2014Sadeqzadeh E, De Bock CE, Wojtalewicz N, Holt JE, Smith ND, Dun MD, et al., 'Furin processing dictates ectodomain shedding of human FAT1 cadherin', Experimental Cell Research, 323 41-55 (2014) [C1]

Fat1 is a single pass transmembrane protein and the largest member of the cadherin superfamily. Mouse knockout models and in vitro studies have suggested that Fat1 influences cell... [more]

Fat1 is a single pass transmembrane protein and the largest member of the cadherin superfamily. Mouse knockout models and in vitro studies have suggested that Fat1 influences cell polarity and motility. Fat1 is also an upstream regulator of the Hippo pathway, at least in lower vertebrates, and hence may play a role in growth control. In previous work we have established that FAT1 cadherin is initially cleaved by proprotein convertases to form a noncovalently linked heterodimer prior to expression on the cell surface. Such processing was not a requirement for cell surface expression, since melanoma cells expressed both unprocessed FAT1 and the heterodimer on the cell surface. Here we further establish that the site 1 (S1) cleavage step to promote FAT1 heterodimerisation is catalysed by furin and we identify the cleavage site utilised. For a number of other transmembrane receptors that undergo heterodimerisation the S1 processing step is thought to occur constitutively but the functional significance of heterodimerisation has been controversial. It has also been generally unclear as to the significance of receptor heterodimerisation with respect to subsequent post-translational proteolysis that often occurs in transmembrane proteins. Exploiting the partial deficiency of FAT1 processing in melanoma cells together with furin-deficient LoVo cells, we manipulated furin expression to demonstrate that only the heterodimer form of FAT1 is subject to cleavage and subsequent release of the extracellular domain. This work establishes S1-processing as a clear functional prerequisite for ectodomain shedding of FAT1 with general implications for the shedding of other transmembrane receptors. © 2014.

DOI10.1016/j.yexcr.2014.02.012
CitationsScopus - 1Web of Science - 1
Co-authorsJanet Holt, Rick Thorne
2014Hatchwell L, Girkin J, Morten M, Collison A, Mattes J, Foster PS, et al., 'Salmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of allergic airways disease¿by modulating protein phosphatase 2A', Journal of Allergy and Clinical Immunology, (2014) [C1]

Background: ß-Agonists are used for relief and control of asthma symptoms by reversing bronchoconstriction. They might also have anti-inflammatory properties, but the underpinnin... [more]

Background: ß-Agonists are used for relief and control of asthma symptoms by reversing bronchoconstriction. They might also have anti-inflammatory properties, but the underpinning mechanisms remain poorly understood. Recently, a direct interaction between formoterol and protein phosphatase 2A (PP2A) has been described in¿vitro. Objective: We sought to elucidate the molecular mechanisms by which ß-agonists exert anti-inflammatory effects in allergen-driven and rhinovirus 1B-exacerbated allergic airways disease (AAD). Methods: Mice were sensitized and then challenged with house dust mite to induce AAD while receiving treatment with salmeterol, formoterol, or salbutamol. Mice were also infected with rhinovirus 1B to exacerbate lung inflammation and therapeutically administered salmeterol, dexamethasone, or the PP2A-activating drug (S)-2-amino-4-(4-[heptyloxy]phenyl)-2-methylbutan-1-ol (AAL[S]). Results: Systemic or intranasal administration of salmeterol protected against the development of allergen- and rhinovirus-induced airway hyperreactivity and decreased eosinophil recruitment to the lungs as effectively as dexamethasone. Formoterol and salbutamol also showed anti-inflammatory properties. Salmeterol, but not dexamethasone, increased PP2A activity, which reduced CCL11, CCL20, and CXCL2 expression and reduced levels of phosphorylated extracellular signal-regulated kinase 1 and active nuclear factor ¿B subunits in the lungs. The anti-inflammatory effect of salmeterol was blocked by targeting the catalytic subunit of PP2A with small RNA interference. Conversely, increasing PP2A activity with AAL(S) abolished rhinovirus-induced airway hyperreactivity, eosinophil influx, and CCL11, CCL20, and CXCL2 expression. Salmeterol also directly activated immunoprecipitated PP2A in¿vitro isolated from human airway epithelial cells. Conclusions: Salmeterol exerts anti-inflammatory effects by increasing PP2A activity in AAD and rhinovirus-induced lung inflammation, which might potentially account for some of its clinical benefits. © 2013 American Academy of Allergy, Asthma & Immunology.

DOI10.1016/j.jaci.2013.11.014
CitationsScopus - 5Web of Science - 4
Co-authorsJoerg Mattes, Paul Foster, Nikki Verrills
2013Smith TB, Dun MD, Smith ND, Curry BJ, Connaughton HS, Aitken RJ, 'The presence of a truncated base excision repair pathway in human spermatozoa that is mediated by OGG1', JOURNAL OF CELL SCIENCE, 126 1488-1497 (2013) [C1]
DOI10.1242/jcs.121657Author URL
CitationsScopus - 14Web of Science - 11
Co-authorsBen Curry, John Aitken
2012Dun MD, Anderson AL, Bromfield EG, Asquith KL, Emmett BJ, McLaughlin EA, et al., 'Investigation of the expression and functional significance of the novel mouse sperm protein, a disintegrin and metalloprotease with thrombospondin type 1 motifs number 10 (ADAMTS10)', International Journal of Andrology, 35 572-589 (2012) [C1]
DOI10.1111/j.1365-2605.2011.01235.x
CitationsScopus - 6Web of Science - 5
Co-authorsJohn Aitken, Eileen Mclaughlin, Brett Nixon
2012Dun MD, Aitken RJ, Nixon B, 'The role of molecular chaperones in spermatogenesis and the post-testicular maturation of mammalian spermatozoa', Human Reproduction Update, 18 420-435 (2012) [C1]
DOI10.1093/humupd/dms009
CitationsScopus - 10Web of Science - 10
Co-authorsJohn Aitken, Brett Nixon
2011Redgrove KA, Anderson AL, Dun MD, McLaughlin EA, O'Bryan MK, Aitken RJ, Nixon B, 'Involvement of multimeric protein complexes in mediating the capacitation-dependent binding of human spermatozoa to homologous zonae pellucidae', Developmental Biology, 356 460-474 (2011) [C1]
DOI10.1016/j.ydbio.2011.05.674
CitationsScopus - 20Web of Science - 22
Co-authorsBrett Nixon, Eileen Mclaughlin, John Aitken
2011Dun MD, Smith ND, Baker MA, Lin M, Aitken RJ, Nixon B, 'The chaperonin containing TCP1 complex (CCT/TRiC) is involved in mediating sperm-oocyte interaction', Journal of Biological Chemistry, 286 36875-36887 (2011) [C1]
DOI10.1074/jbc.m110.188888
CitationsScopus - 19Web of Science - 17
Co-authorsMark Baker, Brett Nixon, Minjie Lin, John Aitken
Show 10 more journal articles

Conference (8 outputs)

YearCitationAltmetricsLink
2014Dun MD, Chalkley RJ, Keene S, Bradshaw RA, Hondermarck H, 'Proteomics versus Transcriptomics for the Identification of Cancer Biomarkers: the Case of Brain-derived Metastatic Breast Cancer Cells', MOLECULAR & CELLULAR PROTEOMICS (2014) [E3]
Author URL
Co-authorsHubert Hondermarck
2014Dun MD, Kahl RGS, Flanagan H, Cairns MMJ, Smith ND, Enjeti AK, et al., 'IDENTIFICATION OF ONCOGENIC SIGNALLING PATHWAYS IN ACUTE MYELOID LEUKAEMIA (AML) PATIENTS BY PHOSPHOPROTEOMICS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsNikki Verrills, Murray Cairns
2014De Iuliis GN, Verrills NM, Dun MD, 'IN SILICO ANALYSIS OF THE TARGETS OF SMALL-MOLECULE, ANTI-CANCER COMPOUNDS FOR IMPROVED CANCER THERAPEUTICS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsNikki Verrills, Geoffry DeiuliIs
2014Gilbert J, Dun MD, De Iuliis GN, McCluskey A, Sakoff JA, 'SELECTIVELY TARGETING BREAST CANCER CELLS VIA CHECKPOINT ACTIVATION', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsGeoffry DeiuliIs, Adam Mccluskey, Jennette Sakoff
2013Dun MD, Smith AM, Kahl RGS, Smith ND, Khanna A, Don AS, et al., 'Unraveling the mechanism of action: drugs that activate the tumor suppressor 2A.', CANCER RESEARCH, Washington, DC (2013) [E3]
DOI10.1158/1538-7445.AM2013-2038Author URL
Co-authorsNikki Verrills
2012Aitken RJ, Nixon B, Redgrove KA, Dun M, Baker MA, 'The molecular origins of defective sperm function', HUMAN REPRODUCTION, Istanbul, TURKEY (2012) [E3]
Author URL
Co-authorsMark Baker, John Aitken, Brett Nixon
2011Dun MD, Aitken JR, Nixon B, 'The CCT/TRiC Complex Is Involved in Mediating Sperm-Oocyte Interaction', BIOLOGY OF REPRODUCTION, Portland, OR (2011) [E3]
Author URL
Co-authorsBrett Nixon, John Aitken
2010Dun MD, Aitken RJ, Nixon B, 'The Chaperonin Containing TCP-1 (CCT/TRIC) Multisubunit Complex is Involved in Mediating Sperm-Oocyte Interactions', Reproduction, Fertility and Development, Sydney (2010) [E3]
Co-authorsBrett Nixon, John Aitken
Show 5 more conferences
Edit

Grants and Funding

Summary

Number of grants9
Total funding$1,149,635

Click on a grant title below to expand the full details for that specific grant.


20151 grants / $25,000

Defining the role of shwachman-bodien diamond syndrome protein (SBDS) in PP2A inhibition in acute myeloid leukaemia (AML)$25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Matt Dun, Doctor Nikki Verrills
SchemeResearch Grant
RoleLead
Funding Start2015
Funding Finish2015
GNoG1500757
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

20144 grants / $992,539

Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia$600,000

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamDoctor Matt Dun, Doctor Nikki Verrills, Associate Professor Martin Larsen
SchemeEarly Career Fellowship
RoleLead
Funding Start2014
Funding Finish2014
GNoG1300952
Type Of FundingOther Public Sector - State
Category2OPS
UONY

Tetraspanin CD9; more than just an exosome marker - A novel biomarker to target for prostate cancer$300,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Jude Weidenhofer, Doctor Kathryn Skelding, Doctor Matt Dun, Ms Belinda Goldie, Miss Danielle Bond
SchemeProject Grant
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1400921
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia$67,539

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Matt Dun, Doctor Nikki Verrills
SchemeProject Grant
RoleLead
Funding Start2014
Funding Finish2014
GNoG1301353
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Defining the role of shwachman-bodien diamond syndrome protein (SBDS) in PP2A inhibition in acute myeloid leukaemia (AML).$25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Matt Dun, Doctor Nikki Verrills
SchemeProject Grant
RoleLead
Funding Start2014
Funding Finish2014
GNoG1301442
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

20133 grants / $32,096

Proteomics of Cancer$6,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Matt Dun, Doctor Nikki Verrills, Dr Anoop Enjeti
SchemeProject Grant
RoleLead
Funding Start2013
Funding Finish2013
GNoG1300054
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

American Association of Cancer Research, Washington Convention Centre Washington DC USA, 6 - 10 April 2012$1,500

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding bodyUniversity of Newcastle - Faculty of Health and Medicine
Project TeamDoctor Matt Dun
SchemeTravel Grant
RoleLead
Funding Start2013
Funding Finish2013
GNoG1201225
Type Of FundingInternal
CategoryINTE
UONY

20121 grants / $100,000

Cancer Institute of NSW Hunter Translation Cancer Research Fellowship$100,000

Fellowship to investigate the mechanism of action of novel anti-cancer compounds.
Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project Team
SchemeTranslational Cancer Research Unit
RoleLead
Funding Start2012
Funding Finish2013
GNo
Type Of FundingExternal
CategoryEXTE
UONY
Edit

Research Supervision

Current Supervision

CommencedResearch Title / Program / Supervisor Type
2015Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia
Medical Science, Faculty of Health and Medicine
Co-Supervisor
2015Identifying the Functional Role of SBDS Protein, A Novel Drug Target in Acute Myeloid Leukaemia
Medical Science, Faculty of Health and Medicine
Co-Supervisor
2015PPP2R2A - A Novel Biomarker and Therapeutic Target for Luminal B Breast Cancer
Medical Science, Faculty of Health and Medicine
Co-Supervisor
2014Chronic Obstructive Pulmonary Disease (COPD)
Microbiology, Faculty of Health and Medicine
Co-Supervisor
Edit

News

Matt Dun

$1.5m to Newcastle researchers to unlock cancer secrets

February 21, 2014

Three University of Newcastle cancer researchers have been recognised with Cancer Institute NSW Early Career Fellowships, totalling more than $1.5 million.

Dr Matt Dun

Position

Cancer Institute NSW EC Fellow
Molecular Oncology
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Contact Details

Emailmatt.dun@newcastle.edu.au
Phone(02) 4921 5693
Fax (02) 4921 6903

Office

RoomLS3.33
BuildingLife Sciences Building
LocationCallaghan
University Drive
Callaghan, NSW 2308
Australia
Edit